

Sub H2 /
F 2

86. (Twice Amended) A therapeutic agent for stimulating the immune system comprising an isolated peptide or protein and a pharmaceutically inert carrier, wherein the amino acid sequence of SEQ ID NO:5 comprises the amino acid sequence of the peptide or protein, wherein the peptide or protein has lectinic properties, and wherein the peptide or protein is recognized by an antibody specific to an isolated peptide or protein having lectinic properties and comprising the amino acid sequence of SEQ ID NO:5.

87. (Amended) A therapeutic agent for stimulating the immune system comprising an isolated peptide or protein, wherein the amino acid sequence of SEQ ID NO:5 comprises the amino acid sequence of the peptide or protein, wherein the peptide or protein has lectinic properties, and wherein the peptide or protein is recognized by an antibody specific to an isolated peptide or protein having lectinic properties and comprising the amino acid sequence of SEQ ID NO:5, and further comprising interleukin-2.

Please add the following new claims:

90. (New) A therapeutic agent according to claim 76, formulated for parenteral administration.

91. (New) A therapeutic agent according to claim 86, formulated for parenteral administration.

✓ 92. (New) A therapeutic agent for stimulating the immune system comprising an isolated peptide or protein having lectinic properties and comprising the amino acid sequence of SEQ ID NO:1, in monomer or dimer form.

F 3
✓ 93. (New) A therapeutic agent for stimulating the immune system comprising an isolated peptide or protein having lectinic properties and comprising the amino acid sequence of SEQ ID NO:3, in monomer or dimer form.

✓ 94. (New) A therapeutic agent for stimulating the immune system comprising an isolated peptide or protein having lectinic properties and comprising the amino acid sequence of SEQ ID NO:4, in monomer or dimer form.

Sub H3 ✓ 95. (New) A therapeutic agent for stimulating the immune system comprising an isolated peptide or protein having lectinic properties and comprising the amino acid sequence of SEQ ID NO:5, in monomer or dimer form.

✓ 96. (New) A therapeutic agent for stimulating the immune system comprising an isolated peptide or protein having lectinic properties and comprising the amino acid sequence of SEQ ID NO:6, in monomer or dimer form.

✓ 97. (New) A method of stimulating the immune system, comprising administering, to a subject in need of such stimulation, an isolated peptide or protein having lectinic properties and comprising the amino acid sequence of SEQ ID NO:1, and a pharmaceutically inert carrier.

Sub H4 F3 ✓ 98. (New) A method of stimulating the immune system, comprising administering, to a subject in need of such stimulation, an isolated peptide or protein having lectinic properties and comprising the amino acid sequence of SEQ ID NO:3, and a pharmaceutically inert carrier.

✓ 99. (New) A method of stimulating the immune system, comprising administering, to a subject in need of such stimulation, an isolated peptide or protein having lectinic properties and comprising the amino acid sequence of SEQ ID NO:4, and a pharmaceutically inert carrier.

✓ 100. (New) A method of stimulating the immune system, comprising administering, to a subject in need of such stimulation, an isolated peptide or protein having lectinic properties and comprising the amino acid sequence of SEQ ID NO:5, and a pharmaceutically inert carrier.

✓ 101. (New) A method of stimulating the immune system, comprising administering, to a subject in need of such stimulation, an isolated peptide or protein having lectinic properties and comprising the amino acid sequence of SEQ ID NO:6, and a pharmaceutically inert carrier.

102. (New) A therapeutic agent as claimed in claim 70, additionally comprising an inert pharmaceutical carrier.

103. (New) A therapeutic agent as claimed in claim 72, additionally comprising an inert pharmaceutical carrier.

104. (New) A therapeutic agent as claimed in claim 74, additionally comprising an inert pharmaceutical carrier.

105. (New) A therapeutic agent as claimed in claim 78, additionally comprising an inert pharmaceutical carrier.

106. (New) A therapeutic agent according to claim 102, formulated for parenteral administration.

107. (New) A therapeutic agent according to claim 103, formulated for parenteral administration.

108. (New) A therapeutic agent according to claim 104, formulated for parenteral administration.

109. (New) A therapeutic agent according to claim 105, formulated for parenteral administration.